

Diary No: 19201
Dated: 03.04.2020

F. No. ND/CT/20/000022
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

Tele No.011-23236965
Fax.No.011-23236973

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated:

29 DEC 2021

To

M/s Sandoz private Ltd.,
MIDC Plot No. 8-A/2, 8-B. T.T.C. Industrial Area,
Kalwe Block, Village Digha, Navi Mumbai,
Maharashtra -400708

Subject: Grant of Permission to conduct Phase IV Clinical Trial entitled "A Phase IV, prospective, multicenter, open-label, non-comparative, interventional study to assess the safety of alpelisib plus fulvestrant, in men and post-menopausal women with HR-positive, HER2-negative, advanced breast cancer (aBC) with a PIK3CA mutation, whose disease has progressed on or after endocrine based treatment." - regarding.

Sir,

With reference to your application no. ND/CT/20/000022 dated 03.04.2020, please find enclosed herewith the permission in Form CT-06, No. **CT/ND/205/2021** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trial Rules, 2019**.

This permission is subject to the conditions, as mentioned below.

Yours faithfully



(Dr. V. G. Somani)
Central Licensing Authority

Condition of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to

clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) **Phase IV Clinical trial study should be conducted with 100 patients as per the recommendation of SEC held on dated 06.08.2021 and 10.08.2021.**
- (xx) **Status update of the study should be submitted to CDSCO in every six months.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW
DRUG****29 DEC 2021**Number of the permission and date of issue **CT/ND/205/2021** dated _____

1. The Central Licensing Authority hereby permits M/s Sandoz private Ltd., MIDC Plot No. 8-A/2, B. T.T.C. Industrial Area, Kalwe Block, Village Digha, Navi Mumbai, Maharashtra - 400708 to conduct clinical trial of the new drug as per Protocol no. **CBYL719CIN01, Version No. 01 & Dated 01.04.2020** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial sites: -

Names of the new drug or investigational new drug:	Alpelisib tablet
Therapeutic class:	Antineoplastic agent
Dosage form:	Tablets
Composition:	Each Tablet Contains Alpelisib.....50mg/150 mg/200 mg
Indications	Alpelisib is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

New Delhi

Date.....

29 DEC 2021
(Dr. V. G. Somani)**Central Licensing Authority
Stamp**

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kottla Road, I.T.O.
New Delhi-110002

Details of clinical trial site			
Sl No.	Investigator Name	Address of Site	Name of Ethics Committee and address with Ethics Committee registration No
01	Dr. Chanchal Goswami	Medica Superspeciality Hospital, 127, Mukundapur,	Clinical Research Ethics Committee, Medica Superspeciality Hospital, 127, Mukundapur, E.M.Bypass, Kolkata-700099

		E.M.Bypass Kolkata-700099	ECR/202/Inst/WB/2013/RR-19
02	Dr. Shekar Patil	Health Care Global Enterprises Limited, HCG Towers, #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore-560027, Karnataka, India	HCG-Central Ethics Committee, HCG Towers, Tower-4, 5th Floor, #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore-560027, Karnataka, India ECR/386/Inst/KA/2013/RR-19
03	Dr. Sudeep Gupta	Address 1-Tata Memorial Hospital, Tata Memorial Centre, Dr. Ernest Borges Marg, Parel, Mumbai-400012, Maharashtra, India Address 2-Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Sector-22, Ove Village Kharghar, Navi Mumbai-410210, Maharashtra, India	Institution Ethics Committee (IEC)-I, 3rd Floor, IRB, Main Building, Tata Memorial Hospital, Dr. Ernest Borges Marg, Parel (E), Mumbai-400012, Maharashtra, Institution Ethics Committee (IEC)-II, 3rd Floor, IRB, Main Building, Tata Memorial Hospital, Dr. Ernest Borges Marg, Parel (E), Mumbai-400012, Maharashtra, India Institution Ethics Committee (IEC)-III, Advanced Centre for Treatment Research and Evaluation in Cancer (ACTREC), Paymaster Shodhika, First Floor, Sector-22, Ove Village Kharghar, Navi Mumbai-410210, I. ECR/170/Inst/MH/2013/RR-19 II. ECR/414/Inst/MH/2013/RR-19 III. ECR/149/Inst/MH/2013/RR-19
04	Dr. Dinesh Chandra Doval	Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi-110085	Institutional Review Board, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi-110085 ECR/10/Inst/DC/2013/RR-19
05	Dr. Vamshi Krishna M.	Apollo Cancer Hospitals, Apollo Hospitals, Jubilee Hills, Hyderabad-500096	Institution Ethics Committee-Clinical Studies, Apollo Hospitals Enterprise Limited, Hyderabad, Apollo research and innovations, Jubilee hills, Apollo Health City, Hyderabad, Shaikpet, Hyderabad, Telangana-500033, India ECR/38/Inst/AP/2013/RR-19